F-group (family)
2486.1.1.2 CLP_protease
Ligands and drugs
3,237
Member domains
1,151
with ligand contacts (≤ 4 Å)
35.6% of members
753
with DrugDomain annotations
23.3% of members
408
with a DrugBank compound
12.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2486.1.1.2 belongs to X-group 2486 ClpP/crotonase, which binds 9.1 ligand superclasses per 20 proteins, broader than 82% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04519 | OCA | Caprylic acid | 28 |
| DB00149 | LEU | Leucine | 14 |
| DB03309 | NHE | N-cyclohexyltaurine | 14 |
| DB07571 | CMQ | N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)-2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]-L-LEUCINAMIDE | 14 |
| DB00188 | BO2 | Bortezomib | 7 |
| DB04491 | DFP | Diisopropylphosphono Group | 7 |
| DB04464 | FME | N-Formylmethionine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| BO2 | N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE | 133 |
| MGmetal | MAGNESIUM ION | 95 |
| VSZ | Cystargolide A (bound) | 70 |
| Kmetal | POTASSIUM ION | 49 |
| NAmetal | SODIUM ION | 42 |
| CAmetal | CALCIUM ION | 32 |
| 9DF | (6S,9aS)-6-[(2S)-butan-2-yl]-8-(naphthalen-1-ylmethyl)-4,7-bis(oxidanylidene)-N-[4,4,4-tris(fluoranyl)butyl]-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide | 28 |
| AI4 | 4-[1-[3-[4-[(4-fluoranyl-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-quinazolin-7-yl]oxypropyl]piperidin-4-yl]benzamide | 28 |
| JT7 | N-[(1R)-1-borono-3-methylbutyl]-N~2~-(2-chloro-4-methoxybenzene-1-carbonyl)-L-leucinamide | 28 |
| USU | (5S,6S,9aS)-N-[(4-fluorophenyl)methyl]-6-methyl-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide | 28 |
| ZGV | 4-[(1E)-3-{[(2E,4E,6E,8S)-8-hydroxy-4-methyldeca-2,4,6-trienoyl]amino}-3-oxoprop-1-en-1-yl]azete-1(2H)-carboxylic acid | 28 |
| ZIL | N-[(benzyloxy)carbonyl]-L-isoleucyl-L-leucine | 28 |
| EZA | N-[(6aS,12S,15aS,17R,21R,23aS)-17,21-dimethyl-6,11,15,20,23-pentaoxooctadecahydro-2H,6H,11H,15H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13]oxatetraazacyclohexadecin-12-yl]-3,5-difluoro-Nalpha-[(2E)-hept-2-enoyl]-L-phenylalaninamide | 21 |
| X3O | 2-{bis[5-(trifluoromethyl)pyridin-2-yl]phosphoryl}-2-methyl-N-(2-{[2-(trifluoromethyl)phenyl]sulfanyl}ethyl)propanamide | 20 |
| MRD | (4R)-2-METHYLPENTANE-2,4-DIOL | 18 |
| CL | CHLORIDE ION | 17 |
| KHS | N-{2-[(2-chlorophenyl)sulfanyl]ethyl}-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]sulfonyl}propanamide | 16 |
| 5C2 | 1-(propan-2-yl)-N-{[2-(thiophen-2-yl)-1,3-oxazol-4-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide | 14 |
| 6V8 | [(1~{R})-1-[2-[[2,5-bis(chloranyl)phenyl]carbonylamino]ethanoylamino]-3-methyl-butyl]boronic acid | 14 |
| 7SR | (6S,9aS)-N-[(4-bromophenyl)methyl]-6-[(2S)-butan-2-yl]-8-(naphthalen-1-ylmethyl)-4,7-bis(oxidanylidene)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide | 14 |